Trial Profile
Randomized, open-label, parallel-group, multi-centre phase II clinical trial of active cellular immunotherapy with prepapration DCVAC/PCa in patients with localized high-risk prostate cancer after primary radiotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Stapuldencel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 12 Nov 2018 Status changed from active, no longer recruiting to completed.
- 22 Mar 2012 New trial record